BCR-ABL DERIVED PEPTIDE VACCINES FOR CHRONIC MYELOID LEUKAEMIA

n/

PERSISTENCE OF PH+/CD34+ CELLS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN PROLONGED COMPLETE CYTOGENETIC REMISSION FOLLOWING IMATINIB MESYLATE TREATMENT

n/

Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma

Twenty-five elderly patients with untreated indolent non-Hodgkin lymphoma were treated with oral fludarabine 25 mg/m2/d (40 mg total dose) and cyclophosphamide 150 mg/m2/d, both for four consecutive days, repeated every 28 d for four cycles. In all, 21 (84%) patients were responsive: 10 patients achieved complete remission while partial response was obtained in 11. During an observation period of 37 months, there was an overall survival rate of 70% and a median event-free survival of 20 months. Haematological and extra-haematological toxicity were mild. This reduced-dose Flu-based oral regimen showed good efficacy and was simple to administer on an outpatient basis. © 2007 The Authors

Low-dose oral fludarabine as first-line treatment in lderly patients with indolent non-Hodgkin lymphoma

none8noneFABBRI A; LENOCI M; GOZZETTI A; CHITARRELLI I; OLCESE F; RASPADORI D; M. GOBBI; LAURIA FFabbri, A; Lenoci, M; Gozzetti, A; Chitarrelli, I; Olcese, F; Raspadori, D; Gobbi, Marco; Lauria, F